• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DIH Appoints Scott R. Burell to DIH Holding US, Inc. Board of Directors

    8/8/25 8:00:00 AM ET
    $DHAI
    $MBOT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DHAI alert in real time by email

    NORWELL, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced the appointment of Scott R. Burell to its Board of Directors.

    Scott R. Burell is a seasoned healthcare finance executive with over two decades of experience leading public life sciences companies through complex transactions and growth phases. Currently serving as Chief Financial Officer and Secretary of AIVITA Biomedical, Inc., an immuno-oncology company, Mr. Burell previously served as CFO of CombiMatrix Corporation through its successful acquisition by Invitae Corp. He has a proven track record in leading public and private debt and equity financing transactions, corporate reorganizations, and complex M&A activities. Mr. Burell also serves on the Board of Directors of Microbot Medical, Inc. (NASDAQ:MBOT), a medical device company specializing in micro-robotics technologies. He holds Bachelor of Science degrees in Accounting and Business Finance from Central Washington University and is a certified public accountant.

    CEO, Jason Chen, stated: "We are pleased to welcome Scott Burell to our Board of Directors. Scott brings exceptional financial acumen and extensive experience in the life sciences sector, having successfully navigated complex transactions and capital market activities throughout his career. His deep understanding of medical technology companies and proven ability to drive value creation will strengthen our board as we continue executing our growth strategy."

    Mr. Burell commented on the appointment: "I am pleased to join DIH's Board of Directors and contribute to the company's mission of improving lives through advanced rehabilitation technologies. DIH's position in the growing rehabilitation robotics market presents significant opportunities, and I look forward to working with management and my fellow board members to support the company's continued success and value creation for shareholders."

    The Board of Directors now comprises six members, with four independent members, further strengthening the company's commitment to strong governance.

    About DIH Holding US, Inc.

    DIH stands for the vision to "Deliver Inspiration & Health" to improve the daily lives of millions of people with disabilities and functional impairments through providing devices and solutions enabling intensive rehabilitation. DIH is a global provider of advanced robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Built through the mergers of global-leading niche technology providers, DIH is a transformative rehabilitation solutions provider and consolidator of a largely fragmented and manual-labor-driven industry.

    Caution Regarding Forward-Looking Statements

    This press release contains certain statements which are not historical facts, which are forward-looking statements within the meaning of the federal securities laws, for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These forward-looking statements include certain statements made with respect to the business combination, the services offered by DIH and the markets in which it operates, and DIH's projected future results. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions provided for illustrative purposes only, and projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These risks and uncertainties include, but are not limited to: general economic, political and business conditions; the ability of DIH to achieve its projected revenue, the failure of DIH realize the anticipated benefits of the recently-completed business combination and access to sources of additional debt or equity capital if needed. While DIH may elect to update these forward-looking statements at some point in the future, DIH specifically disclaims any obligation to do so.

    Investor Contact

    Louisa Smith

    [email protected]



    Primary Logo

    Get the next $DHAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DHAI
    $MBOT

    CompanyDatePrice TargetRatingAnalyst
    Microbot Medical Inc.
    $MBOT
    2/10/2026$5.00Buy
    B. Riley Securities
    Microbot Medical Inc.
    $MBOT
    12/3/2025$5.50Buy
    Roth Capital
    More analyst ratings

    $DHAI
    $MBOT
    SEC Filings

    View All

    Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Microbot Medical Inc. (0000883975) (Filer)

    3/24/26 8:30:06 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Microbot Medical Inc. (0000883975) (Filer)

    3/17/26 9:27:19 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Microbot Medical Inc. (0000883975) (Filer)

    3/10/26 8:30:31 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DHAI
    $MBOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Microbot Medical with a new price target

    B. Riley Securities initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.00

    2/10/26 8:01:31 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roth Capital initiated coverage on Microbot Medical with a new price target

    Roth Capital initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.50

    12/3/25 8:38:40 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DHAI
    $MBOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Vaknin Rachel

    4 - Microbot Medical Inc. (0000883975) (Issuer)

    2/20/26 4:45:18 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chairman, President and CEO Gadot Harel

    4 - Microbot Medical Inc. (0000883975) (Issuer)

    2/20/26 4:45:22 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by General Manager, CTO Sharon Simon

    4 - Microbot Medical Inc. (0000883975) (Issuer)

    2/20/26 4:45:19 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DHAI
    $MBOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Microbot Medical® Strengthens LIBERTY® Endovascular Robotic System Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical Journal

    Being Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study Company Remains Focused on Expanding Evidence-Based Data to Support Broader Commercial Adoption of the LIBERTY System HINGHAM, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, which is already garnering medical and industry attention, today announced the publication of an article in the Journal of Vascular and Interventional Radiology (JVIR), titled "In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Per

    3/24/26 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical® to Participate at the 38th Annual Roth Conference

    HINGHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will participate in the Roth Annual Growth Conference, being held March 22-24 in Laguna Niguel, CA. The conference is a premier event that brings together growth companies, institutional investors, and industry leaders for presentations, panel discussions, and one-on-one meetings. Harel Gadot, CEO, President & Chairman of Microbot Medical will be presenting live via a fireside Q&A discussion at 4:00 pm PT on Monday, March 23rd. Mr. Gadot will highlight the Company's recent achievements, and how LIBERTY is

    3/17/26 8:40:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time

    HINGHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will be participating at the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16-19, 2026. This marks the first time the Company has been invited to participate in this conference, reflecting growing market interest in the Company. Harel Gadot, CEO, President & Chairman will present live at 8:40 am ET on Thursday, March 19th. Mr. Gadot will highlight recent achievements from LIBERTY's limited market release and review key market growth drivers that the Company believes

    3/10/26 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DHAI
    $MBOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DIH Holdings US Inc.

    SC 13G/A - DIH HOLDING US, INC. (0001883788) (Subject)

    11/14/24 6:07:49 PM ET
    $DHAI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by DIH Holdings US Inc.

    SC 13G/A - DIH HOLDING US, INC. (0001883788) (Subject)

    11/14/24 12:46:18 PM ET
    $DHAI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by DIH Holdings US Inc.

    SC 13D - DIH HOLDING US, INC. (0001883788) (Subject)

    2/20/24 5:18:47 PM ET
    $DHAI
    Medical/Dental Instruments
    Health Care

    $DHAI
    $MBOT
    Leadership Updates

    Live Leadership Updates

    View All

    DIH Announces Fiscal 2025 Fourth Quarter and Fiscal Year End Financial Results

    NORWELL, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH" or the "Company") (NASDAQ:DHAI), a global provider of advanced robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced financial results for the fiscal 2025 fourth quarter and fiscal year ended March 31, 2025. Recent Highlights Revenue of $62.9 million for the fiscal year ended March 31, 2025, representing a decrease of 2.5% over the prior year Device revenue of $49.7

    10/20/25 5:05:09 PM ET
    $DHAI
    Medical/Dental Instruments
    Health Care

    DIH Appoints Barrett Mooney, Ph.D to DIH Holding US, Inc. Board of Directors

    NORWELL, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced the appointment of Barrett Mooney, Ph.D. to its Board of Directors. Barrett Mooney, Ph.D., has an extensive track record of growing complex and manufacturing related businesses. He currently provides strategic advisory services to growing high-technology private and public compan

    9/8/25 4:46:27 PM ET
    $DHAI
    Medical/Dental Instruments
    Health Care

    DIH Appoints Scott R. Burell to DIH Holding US, Inc. Board of Directors

    NORWELL, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced the appointment of Scott R. Burell to its Board of Directors. Scott R. Burell is a seasoned healthcare finance executive with over two decades of experience leading public life sciences companies through complex transactions and growth phases. Currently serving as Chief Financia

    8/8/25 8:00:00 AM ET
    $DHAI
    $MBOT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)